Bat­tered by mixed PhI­II da­ta, Treve­na ax­es R&D staff and hun­kers down around lead pain drug

Eight months af­ter Treve­na {TRVN} was ham­mered over some mixed Phase III re­sults for its new pain ther­a­py, the biotech is slash­ing its re­search group and cir­cling the wag­ons around its lead ther­a­py in pur­suit of a new drug ap­proval from the FDA.

Twen­ty-one staffers large­ly from the re­search arm are be­ing cut — 30% of its to­tal work­force. And chief sci­en­tif­ic of­fi­cer Michael Lark is head­ed to the ex­it as well in mid-De­cem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.